Skip to content

Scaling-up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States – a Rural and Urban Comparison

Research output: Contribution to journalArticle

Standard

Scaling-up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States – a Rural and Urban Comparison. / Fraser, Hannah; Vellozzi, Claudia; Hoerger, Thomas; Evans, Jennifer; Kral, Alex H.; Havens, Jennifer; Young, April; Stone, Jack; Handanagic, Senad; Hariri, Susan; Barbosa, Carolina; Hickman, Matthew; Leib, Alyssa; Martin, Natasha; Nerlander, Lina; Raymond, Henry; Page, Kimberly; Zibbell, Jon; Ward, John; Vickerman, Peter.

In: American Journal of Epidemiology, Vol. 188, No. 8, kwz097, 31.05.2019, p. 1539–1551.

Research output: Contribution to journalArticle

Harvard

Fraser, H, Vellozzi, C, Hoerger, T, Evans, J, Kral, AH, Havens, J, Young, A, Stone, J, Handanagic, S, Hariri, S, Barbosa, C, Hickman, M, Leib, A, Martin, N, Nerlander, L, Raymond, H, Page, K, Zibbell, J, Ward, J & Vickerman, P 2019, 'Scaling-up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States – a Rural and Urban Comparison', American Journal of Epidemiology, vol. 188, no. 8, kwz097, pp. 1539–1551. https://doi.org/10.1093/aje/kwz097

APA

Fraser, H., Vellozzi, C., Hoerger, T., Evans, J., Kral, A. H., Havens, J., ... Vickerman, P. (2019). Scaling-up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States – a Rural and Urban Comparison. American Journal of Epidemiology, 188(8), 1539–1551. [kwz097]. https://doi.org/10.1093/aje/kwz097

Vancouver

Fraser H, Vellozzi C, Hoerger T, Evans J, Kral AH, Havens J et al. Scaling-up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States – a Rural and Urban Comparison. American Journal of Epidemiology. 2019 May 31;188(8):1539–1551. kwz097. https://doi.org/10.1093/aje/kwz097

Author

Fraser, Hannah ; Vellozzi, Claudia ; Hoerger, Thomas ; Evans, Jennifer ; Kral, Alex H. ; Havens, Jennifer ; Young, April ; Stone, Jack ; Handanagic, Senad ; Hariri, Susan ; Barbosa, Carolina ; Hickman, Matthew ; Leib, Alyssa ; Martin, Natasha ; Nerlander, Lina ; Raymond, Henry ; Page, Kimberly ; Zibbell, Jon ; Ward, John ; Vickerman, Peter. / Scaling-up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States – a Rural and Urban Comparison. In: American Journal of Epidemiology. 2019 ; Vol. 188, No. 8. pp. 1539–1551.

Bibtex

@article{8727ece2484c45e48be4650d2fd67178,
title = "Scaling-up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States – a Rural and Urban Comparison",
abstract = "In the U.S. Hepatitis C virus (HCV) transmission is increasing among people who inject drugs (PWID). Many regions have insufficient prevention intervention coverage. Using modelling, we investigate the impact of scaling-up prevention and treatment interventions on HCV transmission among PWID in Perry County, Kentucky (PC), and San Francisco, California (SF), where HCV sero-prevalence among PWID is >50{\%}. A greater proportion of PWID access medication-assisted treatment (MAT) or syringe service programs (SSP) in urban SF (established community) than rural PC (young, expanding community). We model the proportion of HCV-infected PWID needing HCV-treatment annually to reduce HCV-incidence by 90{\%} by 2030, with and without MAT scale-up (50{\%} coverage, both settings) and SSP scale-up (PC only) from 2017. With current MAT&SSP coverage during 2017-2030, HCV-incidence will increase in PC (21.3 to 22.6 per 100 person-years (/100pyrs)) and decrease in SF (12.9 to 11.9/100pyrs). With concurrent MAT&SSP scale-up, 5{\%}/year of HCV-infected PWID need HCV-treatment in PC to achieve incidence targets; 13{\%}/year without MAT&SSP scale-up. In SF, a similar proportion need HCV-treatment (10{\%}/year) irrespective of MAT scale-up. Reaching the same impact by 2025 requires increases in treatment rates of 45-82{\%}. Achievable provision of HCV-treatment, alongside MAT&SSP scale-up (PC) and MAT scale-up (SF), could reduce HCV-incidence.",
keywords = "direct-acting-antiviral HCV-treatment, Hepatitis C virus, medication-assisted treatment, modelling, persons who inject drugs, syringe service programs",
author = "Hannah Fraser and Claudia Vellozzi and Thomas Hoerger and Jennifer Evans and Kral, {Alex H.} and Jennifer Havens and April Young and Jack Stone and Senad Handanagic and Susan Hariri and Carolina Barbosa and Matthew Hickman and Alyssa Leib and Natasha Martin and Lina Nerlander and Henry Raymond and Kimberly Page and Jon Zibbell and John Ward and Peter Vickerman",
year = "2019",
month = "5",
day = "31",
doi = "10.1093/aje/kwz097",
language = "English",
volume = "188",
pages = "1539–1551",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "8",

}

RIS - suitable for import to EndNote

TY - JOUR

T1 - Scaling-up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States – a Rural and Urban Comparison

AU - Fraser, Hannah

AU - Vellozzi, Claudia

AU - Hoerger, Thomas

AU - Evans, Jennifer

AU - Kral, Alex H.

AU - Havens, Jennifer

AU - Young, April

AU - Stone, Jack

AU - Handanagic, Senad

AU - Hariri, Susan

AU - Barbosa, Carolina

AU - Hickman, Matthew

AU - Leib, Alyssa

AU - Martin, Natasha

AU - Nerlander, Lina

AU - Raymond, Henry

AU - Page, Kimberly

AU - Zibbell, Jon

AU - Ward, John

AU - Vickerman, Peter

PY - 2019/5/31

Y1 - 2019/5/31

N2 - In the U.S. Hepatitis C virus (HCV) transmission is increasing among people who inject drugs (PWID). Many regions have insufficient prevention intervention coverage. Using modelling, we investigate the impact of scaling-up prevention and treatment interventions on HCV transmission among PWID in Perry County, Kentucky (PC), and San Francisco, California (SF), where HCV sero-prevalence among PWID is >50%. A greater proportion of PWID access medication-assisted treatment (MAT) or syringe service programs (SSP) in urban SF (established community) than rural PC (young, expanding community). We model the proportion of HCV-infected PWID needing HCV-treatment annually to reduce HCV-incidence by 90% by 2030, with and without MAT scale-up (50% coverage, both settings) and SSP scale-up (PC only) from 2017. With current MAT&SSP coverage during 2017-2030, HCV-incidence will increase in PC (21.3 to 22.6 per 100 person-years (/100pyrs)) and decrease in SF (12.9 to 11.9/100pyrs). With concurrent MAT&SSP scale-up, 5%/year of HCV-infected PWID need HCV-treatment in PC to achieve incidence targets; 13%/year without MAT&SSP scale-up. In SF, a similar proportion need HCV-treatment (10%/year) irrespective of MAT scale-up. Reaching the same impact by 2025 requires increases in treatment rates of 45-82%. Achievable provision of HCV-treatment, alongside MAT&SSP scale-up (PC) and MAT scale-up (SF), could reduce HCV-incidence.

AB - In the U.S. Hepatitis C virus (HCV) transmission is increasing among people who inject drugs (PWID). Many regions have insufficient prevention intervention coverage. Using modelling, we investigate the impact of scaling-up prevention and treatment interventions on HCV transmission among PWID in Perry County, Kentucky (PC), and San Francisco, California (SF), where HCV sero-prevalence among PWID is >50%. A greater proportion of PWID access medication-assisted treatment (MAT) or syringe service programs (SSP) in urban SF (established community) than rural PC (young, expanding community). We model the proportion of HCV-infected PWID needing HCV-treatment annually to reduce HCV-incidence by 90% by 2030, with and without MAT scale-up (50% coverage, both settings) and SSP scale-up (PC only) from 2017. With current MAT&SSP coverage during 2017-2030, HCV-incidence will increase in PC (21.3 to 22.6 per 100 person-years (/100pyrs)) and decrease in SF (12.9 to 11.9/100pyrs). With concurrent MAT&SSP scale-up, 5%/year of HCV-infected PWID need HCV-treatment in PC to achieve incidence targets; 13%/year without MAT&SSP scale-up. In SF, a similar proportion need HCV-treatment (10%/year) irrespective of MAT scale-up. Reaching the same impact by 2025 requires increases in treatment rates of 45-82%. Achievable provision of HCV-treatment, alongside MAT&SSP scale-up (PC) and MAT scale-up (SF), could reduce HCV-incidence.

KW - direct-acting-antiviral HCV-treatment

KW - Hepatitis C virus

KW - medication-assisted treatment

KW - modelling

KW - persons who inject drugs

KW - syringe service programs

U2 - 10.1093/aje/kwz097

DO - 10.1093/aje/kwz097

M3 - Article

VL - 188

SP - 1539

EP - 1551

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 8

M1 - kwz097

ER -